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Abstract
Genital herpes is a major risk factor in acquiring human immunodeficiency virus type-1 (HIV-1) infection and is caused by
both Herpes Simplex virus type 1 (HSV-1) and HSV-2. The amphipathic peptide C5A, derived from the non-structural
hepatitis C virus (HCV) protein 5A, was shown to prevent HIV-1 infection but neither influenza nor vesicular stomatitis virus
infections. Here we investigated the antiviral function of C5A on HSV infections. C5A efficiently inhibited both HSV-1 and
HSV-2 infection in epithelial cells in vitro as well as in an ex vivo epidermal infection model. C5A destabilized the integrity of
the viral HSV membrane. Furthermore, drug resistant HSV strains were inhibited by this peptide. Notably, C5A-mediated
neutralization of HSV-1 prevented HIV-1 transmission. An in vitro HIV-1 transmigration assay was developed using primary
genital epithelial cells and HSV infection increased HIV-1 transmigration. Treatment with C5A abolished HIV-1
transmigration by preventing HSV infection and by preserving the integrity of the genital epithelium that was severely
compromised by HSV infection. In conclusion, this study demonstrates that C5A represents a multipurpose microbicide
candidate, which neutralizes both HIV-1 and HSV, and which may interfere with HIV-1 transmission through the genital
epithelium.
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Introduction
Genital herpes is the other most prevalent sexually transmitted
infections worldwide and is the most common cause of genital
ulcers. Genital herpes is mainly caused by HSV-2, although an
increasing percentage of the genital herpes is caused by HSV-1
[1–3]. The hallmark of herpesvirus infections is the establishment
of a lifelong, latent infection that can reactivate to cause one or
more rounds of disease. In the USA, 40 to 60 million people are
HSV-2-infected, with an incidence of 1–2 million new infections
and 600,000–800,000 clinical cases per year [3]. Prevalence in the
30–40 year-old population is about 30% [3]. There is a significant
medical need for prevention and treatment of HSV-2 since there
are no licensed vaccines currently available and therapeutic
treatment requires repeated dosing with antiviral products.
Importantly, genital herpes is a risk factor to acquire HIV-1
infection by sexual contact, by increasing both infectivity and
susceptibility to acquire HIV-1 [1–3]. Genital herpes is charac-
terized by the formation of papules and vesicles, which can
progress into pustules and ulcers. Ulceration could disrupt the
mucosal barrier and thereby abrogated the protective barrier
function of the epithelium. Moreover, ulceration could allow HIV-
1 to reach the sub-epithelial dendritic cells (DC), which efficiently
promotes HIV-1 transmission in vitro [4]. Furthermore, target cells
for HIV-1 are attracted to the mucosal sites during HSV-2
infection [4–6], which can result in higher transmission rates.
Thus, there is also an urgent need for novel prophylactic methods,
such as topical microbicides designed for genital application, to
prevent both HSV and HIV-1 transmission. Development of
topical microbicide with dual activity that target both HIV-1 and
HSV may prove a powerful strategy for reducing HIV-1 as
epidemiological studies consistently demonstrate synergy between
these two pathogens.
The short peptide called C5A derived from HCV nonstructural
protein 5A (NS5A) has antiviral activity against HCV and HIV-1
[7–8]. Importantly, C5A represents a novel class of microbicidal
candidates against HIV-1. C5A neutralizes primary HIV-1 and
SIV isolates in nM-mM concentrations without apparent cytotox-
icity to human cells [8]. C5A corresponds to a small (18 amino
acids) N-terminal region (aa 3–20) NS5A (477 amino acids) [7].
The sequence of C5A encompasses the region responsible for the
anchoring of NS5A into the ER membrane [9]. In contrast to C5A
(18 amino acids), full-length NS5A (477 amino acids) does not
inhibit HIV-1 infection [8]. We demonstrated that C5A disrupts
HIV-1, but preserves the integrity of the cellular plasma
membrane [8]. The HIV-1 membrane rupture by C5A is
apparently virus-specific because it does not inhibit the infection
of other enveloped viruses, such as influenza and vesicular
stomatitis viruses [8]. It is unclear whether C5A can prevent co-
infections such as HSV that enhance HIV-1 susceptibility.
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Here we have investigated the antiviral activity of C5A against
HSV-1 and HSV-2. Our data demonstrate that C5A not only
prevents HSV infection but also limits viral dissemination.
Furthermore, the study demonstrates that C5A prevents HSV-
induced HIV-1 susceptibility. Thus, our data show that C5A is an
efficient antiviral peptide that prevents HSV as well as HIV-1
infection. This function might be harnessed in microbicides that
need to prevent HIV-1 transmission.
Results
C5A inhibits HSV-1 and HSV-2 infection in vitro
We investigated whether infection of HSV-1 and -2 could be
inhibited by C5A. Vero cells were infected with HSV-1, HSV-1-
GFP and HSV-2 in the presence of C5A. C5A (5 mM) or control
DMSO was added immediately after adding viruses to target
cells. In the absence of C5A, the cell monolayer was destroyed
after two days and cells exhibited a round morphology, indicative
of HSV infection (Figure 1A, top panels). In contrast, in the
presence of C5A, cell monolayers were mostly unaffected,
suggesting that C5A prevented HSV infection (Figure 1A, bottom
panels). Furthermore, C5A prevented HSV-1 replication in the
cell monolayers as observed by decreased in GFP expression in
HSV-1-GFP infected cultures in the presence of C5A. (Figure 1A,
bottom right panel).
To further measure the efficacy of C5A, Vero cells were infected
with increasing concentrations of HSV (MOI from 0.0001 to 1) in
the presence or absence of C5A. Infection was quantified either by
cell surface expression of HSV gD (Figure 1B, top panels and
bottom left panel) or by GFP content (Figure 1B, bottom right
panel). Remarkably, C5A blocked both HSV-1 and HSV-2
infection at low and intermediate MOI (MOI from 0.0001 to 0.1)
(Figure 1B). Partial inhibition by C5A was observed at very high
MOI (MOI of 1) (Figure 1B, top panels). C5A also blocked HSV
infection in primary human corneal and conjunctival epithelial
cells (Figure 1C).
Next we investigated whether C5A prevents infection in other
cells than epithelial cells. Dendritic cells (DC) are productively
infected with HSV [10–14]. Primary human DC were incubated
with HSV-1 or HSV-2 in the presence or absence of C5A. HSV
infection was quantified by cell surface expression of HSV gD
two days post-infection. Remarkably, C5A strongly reduced
HSV infection of DC (Figure 1D). Together, these results
demonstrate that C5A blocks HSV infection in different target
cells in vitro.
C5A diminishes HSV epidermis infection ex vivo
We next investigated the capacity of C5A to interfere with HSV
infection ex vivo. The primary in vivo target cells for HSV are
keratinocytes [15]. We therefore infected human epidermal sheets
with different concentrations of HSV-1-GFP (MOI of 0.3, 3 and
30). At the moment of infection the sheets were treated with
different concentrations of C5A. After 2 days, sheets were
analyzed by microscopy and flow cytometry. C5A diminished
HSV-1 infection ex vivo (Figure 2A and B). The level of inhibition
was dependent on the inoculum of the virus (Figure 2A and 2B).
Thus, C5A inhibits HSV infection both in vitro and ex vivo.
C5A inhibits acyclovir (ACV)- and gancyclovir (GCV)-
resistant HSV strains
The drugs of choice for HSV treatment are nucleoside
analogues, such as ACV and GCV. Here we examined whether
C5A also neutralizes the infectivity of ACV- and GCV-resistant
HSV isolates [16]. Specifically, Vero cells were infected with
drug-resistant HSV isolates in the presence of increasing
concentrations of ACV, GCV or C5A. Infection was quantified
by real-time PCR (RT-PCR) as described previously [16] and
results expressed as IC50 (Table 1). As described previously [16],
several of the drug-resistant HSV isolates were resistant to ACV
or GCV (Table 1). In contrast, all drug-resistant HSV isolates
were sensitive to C5A (IC50 from 0.3 to 1 mM) (Table 1). These
data demonstrate that C5A can be used to treat drug resistant
HSV infections.
C5A requirements for anti-HSV properties
C5A forms an amphipathic alpha-helical peptide [7–8] that
might be involved in the anti-viral mechanism. To adress this
issue, mutant C5A peptides were generated where an arginine
and a serine in SWLRDIWDWICEVLSDFK wild-type C5A
were displaced to create the SWRLDIWDWICESVLDFK
peptide. Vero cells were infected with HSV and infectivity scored
as described above by measuring GFP content (Figure 3).
Importantly, these amino acid changes, that disturb the peptide
amphipacity, abrogated the anti-HSV effect of C5A (Figure 3).
This suggests that the amphipacity of C5A is a prerequirement
for the anti-HSV effect. On the other hand, scrambling the
hydrophobicity of C5A (SIWRDWVDLICEFLSDWK) signifi-
cantly diminished its anti-HSV activity (Figure 3). Furthermore,
putative disulfide bridges formation is not required for the anti-
HSV activity of C5A, since the cysteine peptide mutant
(SWLRDIWDWI(C)SEVLSDFK) exhibits the same anti-viral
activity as wild-type C5A (Figure 3). Amino acids are chiral and
exist as L or D isomers. Almost all naturally occurring amino
acids are L-amino acids and we investigated whether changes in
chirality affects the antiviral activity of C5A. Therefore, the anti-
HSV efficacy of C5A composed in ‘‘conventional’’ L-amino acids
(L-aa) was compared with that of C5A composed in amino acids
in D configuration (D-aa). Notably, D-aa C5A was significantly
more potent than L-aa C5A in inhibiting HSV infection
(Figure 3). Given that proteases recognize mainly L-amino acids,
it is likely that the endurance of the D-aa peptide in culture
medium (10% FBS) is increased, explaining its enhanced antiviral
activity compared to the L-aa peptide. Supporting this hypoth-
esis, the addition of protease inhibitors together with the L-aa
peptide significantly increased its antiviral potency (data not
shown).
Mechanisms of anti-HSV action of C5A
C5A could inhibit HSV infection by interfering during viral
entry. To address this issue, we conducted a synchronized assay
where Vero cells were exposed to HSV (MOI of 0.1) at 4uC for 2 h
and increasing concentrations of C5A or the non-amphipathic
control C5A variant were added just prior to shifting the
temperature to 37uC (Figure 3). After 2 h, HSV entry was
quantified by measuring amounts of HSV capsid internalized.
Specifically, cells were washed, trypsinized and lysed. Amounts of
internalized virus were quantified by measuring amounts of HSV
capsid in cell lysates by ELISA. Importantly, we found that C5A
prevented HSV entry in a dose-dependent manner (Figure 4A),
suggesting that C5A neutralizes HSV just before or during viral
entry.
C5A is virocidal for HIV-1 by destabilizing it at the level of the
viral membrane [8]. However, C5A does not influence the
infectivity of influenza and vesicular stomatitis (VSV) viruses [7],
suggesting that C5A disrupts the envelope integrity of some viruses
(HIV-1, HCV), but not others (influenza and VSV). We thus asked
whether C5A inhibits HSV, by influencing the integrity of its
membrane. Purified HSV virions were resuspended and incubated
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Figure 1. C5A blocks HSV infection. A. Vero cells were seeded in a 24-well plate and infected with increasing concentrations (MOI from 0.0001 to
1) of HSV-1 (Syn 17), HSV-2 (333) or HSV-1-GFP. C5A (5 mM) or control DMSO was added immediately after adding viruses to target cells. Two days
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with wild-type or the non-amphipathic control C5A variant
(Figure 3) for 30 min at 37uC and immediately loaded over a 20–
70% sucrose density gradient. Each gradient fraction (total of eight
fractions) was analyzed for HSV capsid and gD content by
Western blotting. The sucrose gradient density of each fraction
was determined by measuring the refractive index. Untreated
HSV sediments at a density of 1.24 g/cm3 as demonstrated by the
colocalization of the viral capsid and gD within the gradient
(Figure 4B, bottom left panels). Upon C5A treatment, the
distribution of capsid and gD within the gradient radically differs.
Specifically, gD relocated to the top of the gradient, whereas
capsid migrated deeper in the gradient (Figure 4B, bottom right
panels). We obtained similar results for gB and gH (data not
shown). Altogether these data suggest that C5A partially or
completely destabilized the viral membrane, but kept intact the
structure of the HSV capsid core. The poor infectivity of C5A-
treated HSV virions likely results from the destabilization of their
viral membranes.
C5A thus disrupts the membrane of both HSV (Figure 4B) and
HIV-1 [8], but preserves the integrity of the cellular plasma
membrane [8]. Here, we further verified that C5A exhibits no
toxicity onto primary cells. We conducted a trypan blue exclusion
assay using human peripheral blood monocytic cells (PBMC)
exposed to high concentrations of C5A (2.5 to 100 mM). In
contrast to chloroquine, high concentrations of C5A do not exert
toxicity on PBMC (Figure 4C), further suggesting that although
C5A can disrupt the membrane of viruses, it preserves the integrity
of the cellular plasma membrane.
We found that when higher amounts of purified HIV-1 or HSV
virions (.100 mg/mL of viral capsid) were used, higher amounts
of C5A were required to disrupt viral particles (data not shown).
Nevertheless, the ultimate goal of these studies is to use C5A as a
microbicidal agent at doses of 100–500 mM, which should suffice
to neutralize the expected relatively low amounts of incoming
HIV-1 particles during sexual transmission. It is critical to
emphasize that we recently demonstrated that the topical
application of C5A totally prevented the vaginal transmission of
HIV-1 in humanized bone marrow - liver - thymus (BLT) mice
[unpublished data]. This is the first proof-of-concept that C5A can
be used as a topical microbicidal anti-HIV-1 agent. This also
indicates that C5A preserves its antiviral activities in the genital
environment. This is in accordance with our observation that in
vitro, C5A neutralizes HIV-1 infectivity, even diluted in genital
fluids (i.e., cervical and vaginal fluids, and seminal plasma)
(Table 2). Specifically, seminal plasma was separated from sperm
by centrifugation at 5006g for 10 min. The pH was determined
before and after mixing with C5A diluted in PBS. We found that
the original pH of seminal plasma is approximately 8.0 (n = 8).
Fifty mL of serially two-fold diluted peptide in DMEM medium
were mixed with 50 mL of JR-CSF and 50 mL of seminal plasma
or DMEM. Mixtures were added to TZM reporter cells and
infection scored after 48 h. Similar studies were conducted with
cervical fluid and vaginal mucus. Importantly, even diluted in
seminal plasma or vaginal fluids, C5A blocks HIV-1 infection at a
low mM range (IC50 from 1 to 5 mM) (Table 2).
HSV neutralization by C5A diminishes HIV-1
transmigration through the genital epithelial barrier
HIV-1 is thought to be sexually transmitted by genital
epithelium transmigration. Genital herpes can facilitate HIV-1
acquisition by disrupting the epithelial barrier, thereby increasing
exposure of target cells to virus [2,17–18]. We thus investigated
whether C5A, by neutralizing HSV, would protect epithelial cells
from disruption and therefore slow down HIV-1 transmigration.
We previously developed an in vitro transwell chamber assay that
mimics HIV-1 transcytosis through primary genital epithelial cells
(PGEC) [19]. Specifically, PGEC were seeded onto polycarbonate
membrane transwells and cultured until formation of tight
junctions is achieved. The monolayer on the filter effectively
divides the well into an apical compartment and a basolateral
compartment (Figure 5A). To ensure the integrity of the PGEC
barrier, the elevated transepithelial electrical resistance (TER) of
each monolayer was monitored as well as the paracellular passage
of the extracellular marker inulin. We found that TER was low
at day 1 around 100 Ohm?cm2, peaked at day 2 up to
400 Ohm?cm2 and remained constant for 2 additional days.
HIV-1 (1 ng of p24) was added to the apical surface of PGEC in
the upper chamber of the transwell system for 8 h at 37uC and the
amount of transcytosed virus was quantified by p24 ELISA in the
lower chamber medium in contact with the basal PGEC surface
[19]. We previously determined that HIV-1 transmigration
through PGEC monolayers is maximal after 8 h [19]. Infectivity
of transcytosed HIV-1 after 8 h was analyzed using TZM reporter
target cells [20]. Wild-type (JR-CSF or NL4.3), but not envelope
deficient HIV-1 (DE NL4.3), transmigrated through PGEC
(Figure 5B, top panel), demonstrating that the PGEC layer does
not allow nonspecific transmigration of viruses. Although HIV-1
crosses PGEC as infectious particles (Figure 5B, bottom panel), the
efficiency of transcytosis is extremely poor (less than 0.003% of the
initial inoculum) (Figure 5B, top panel), suggesting that the genital
epithelium serves as a major barrier against HIV-1. We measured
39.8% of viral input present in lower chamber in a control well
with no cells so that one could determine how much HIV-1 crosses
in the setting of ‘‘complete disruption’’ (data not shown).
After establishing the HIV-1 transmigration assay, we defined
conditions that would allow us to examine the enhancing effect of
HSV infection of PGEC on HIV-1 transmigration. To address this
issue, PGEC monolayers were exposed to a low HSV MOI
(0.005). After 2 days, PGEC were washed and exposed this time to
HIV-1. HIV-1 transmigration was quantified 8 h post-HIV-1
exposure. We first found that 55–85% of PGEC were infected 2
days post-HSV exposure (Figure 5C). The integrity of the PGEC
barrier was monitored before and after HSV exposure. HSV
enhanced the passage of FITC-inulin (Figure 5D, top panel) and
decreased the TER of the monolayer (Figure 5D, bottom panel),
whereas ACV (50 mmol/L)) abolished these effects (Figure 5D).
These data confirm that HSV can diminish the impermeability of
the PGEC barrier. It is important to note that despite the fact that
a significant amount of PGEC (55–85%) were infected with the
low HSV MOI (Figure 5C), the integrity of the epithelial barrier
post-infection, HSV-infected cultures (MOI 0.1) were analyzed by microscopy and representative pictures are depicted. B. Two days post-infection,
infection of Vero cells was quantified by FACS either by mouse anti-HSV gD IgG2a immunostaining (HSV-1 Syn 17 and HSV-2 333) or by GFP content
(HSV-1-GFP). For the gD cell surface staining, cells were washed and trypsinized 3 h post-infection to remove the original inoculum, and rabbit FITC-
anti-mouse IgG were used to quantify bound mouse anti-HSV gD IgG. C. Human corneal and conjunctival epithelial cells were exposed for two days
with increasing concentrations of HSV-1-GFP together with C5A (5 mM) or control DMSO. Infection was scored by GFP content. D. Primary human DC
isolated from two donors were incubated with HSV-1 or HSV-2 (MOI of 0.1) together with C5A (5 mM) or control DMSO. HSV infection was quantified
by cell surface expression of HSV gD two days post-infection as described above. Error bars represent standard errors of triplicates. Results are
representative of two independent experiments.
doi:10.1371/journal.pone.0018917.g001
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Figure 2. C5A blocks HSV epidermis infection ex vivo. A. Epidermal sheets were prepared from human skin and infected with increasing
concentrations of HSV-1-GFP (MOI of 0.3, 3 or 30) together with C5A (1, 3 and 10 mM) or control DMSO. Two days post-infection, cell cultures were
analyzed by fluorescence microscopy and representative pictures are depicted. B. Epidermal cells were harvested and analyzed for GFP expression by
flow cytometry. Error bars represent standard errors of duplicates. These results are representative of 2 independent experiments.
doi:10.1371/journal.pone.0018917.g002
C5A as a Multipurpose Anti-HIV-1 Microbicidal Candidate
PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e18917
was still partially preserved 2 days post-HSV infection (Figure 5D).
However, 3–4 days post-HSV infection the PGEC barrier was
severely disrupted (data not shown). Moreover, we found that
higher MOI (i.e., 0.1 to 1) totally disrupt the integrity of the PGEC
barrier already after 2 days (data not shown). Based on these
observations, we chose for all subsequent experiments to use a low
HSV MOI (0.005) for the initial PGEC infection, and to
subsequently expose HSV-infected PGEC to HIV-1 2 days post-
HSV infection. We speculated that these conditions mimic
physiological conditions, where the integrity of the HSV-infected
genital barrier is diminished, but still exists. Interestingly, we
observed that PGEC isolated from various donors were constantly
more resistant to the lytic effect of HSV than immortalized
epithelial cells (i.e., HeLa cells). The origin of this resistance
remains to be understood.
To investigate the effect of HSV infection on HIV-1
transmigration, PGEC monolayers were incubated with HSV-1
or HSV-2 for 2 days, exposed to HIV-1, and amounts of
transcytosed HIV-1 were quantified by p24 ELISA in the basal
chamber 8 h post-HIV-1 exposure. HSV-1 and HSV-2 infections
significantly enhanced HIV-1 crossing (7- and 11-fold, respective-
ly) (Figure 6A). We also analyzed the effect of the nonionic
detergent N9, which was originally thought to be spermicide, but
which not only failed to offer microbicidal protection, but also
increased HIV-1 transmission in vivo [6,21–24]. N9 slightly
enhanced HIV-1 crossing (Figure 6A), likely due to PGEC
cytoxicity as previously described [25]. ACV prevented the
HSV-mediated HIV-1 transmigration enhancement (Figure 6B),
supporting the notion that HSV infection of PGEC causes the
increase of HIV-1 crossing to the lower chamber around disrupted
cells.
Next, the antiviral properties of C5A were investigated. PGEC
monolayers were first exposed to HSV-1 or HSV-2 together with
C5A or the amphipathic control C5A variant for 2 days and
washed to remove peptides. HIV-1 was then added to the apical
surface of PGEC for 8 h at 37uC and amounts of transcytosed
virus were quantified by p24 ELISA in the lower chamber
medium. C5A suppressed the HSV-mediated enhancement of
HIV-1 transmigration (Figure 6C). These results suggest that C5A,
by preventing HSV infection of PGEC (Figure 5C), slows down
the disruption of the integrity of the monolayer (Figure 5D), which
favors HIV-1 transcytosis (Figure 6A and 6B). In conclusion, C5A,
by neutralizing HSV, slows down severely (5–10-fold) the passage
of HIV-1 through the genital epithelial barrier.
Discussion
In this study, we examined the possibility that C5A represents a
multipurpose microbicidal candidate that neutralizes both HIV-1
and HSV. Our data indicate that C5A effectively inhibits both
HSV-1 and HSV-2 infection of epithelial cells in vitro and ex vivo by
destabilizing the viral membrane without affecting cellular
membranes. HSV infection enhances HIV-1 transmission by
affecting the integrity of epithelial layers. Notably, our data
demonstrate that C5A prevents HSV-induced HIV-1 transmission
by preventing HSV replication and thereby disruption of the
epithelial layer in an in vitro HIV-1 transmigration assay. These
data strongly suggest that C5A can be used in strategies to prevent
HSV infection and HSV-induced HIV-1 transmission.
A truly safe and effective microbicide is likely to require a
combination of drugs that target different steps in the HIV-1 life
cycle and provide protection against other STIs known to facilitate
HIV-1 infection such as HSV. Epidemiological studies consistently
demonstrate a strong link between HSV-2 infection and the risk
Table 1. C5A inhibits infectivity of drug-resistant HSV
isolates.
Viruses (HSV) ACV IC50 GCV IC50 C5A IC50
97-1716 3.5 3.9 1
95-2723 45.5 .50 0.43
03-16620 12.5 41.5 0.39
95-1552 4.5 0.7 0.5
119681 4.5 0.4 0.75
98-350 0.2 0.2 0.17
03-2787 0.2 0.2 0.3
HSV-1 GFP ND ND 0.57
The susceptibility of ACV-, and GCV-resistant HSV isolates was determined by
real-time PCR (qPCR) assay. Briefly, Vero cells were inoculated with HSV isolates
for 1 h at 37uC. Viral inoculum was removed and cells were incubated, in
triplicate, with increasing concentrations of ACV (0.05 to 50 mmol/L), GCV (0.05
to 50 mmol/L) or C5A (0.1 to 50 mM). At 24 h after inoculation, the supernatant
was discarded and cells were lysed. Cell lysates were subjected to qPCR as we
described previously [16]. Viral load was determined on the basis of a standard
curve generated on a stock of HSV-1 strain McIntyre. The IC50 (mmol/L) was
defined as the concentration of antiviral drug that reduced viral copies by 50%,
compared with what was observed for infected control cells to which no drug
was added.
doi:10.1371/journal.pone.0018917.t001
Figure 3. C5A requirements for its anti-HSV effect. Vero cells
were seeded in a 24-well plate and infected with HSV-1-GFP (MOI of
0.1). Increasing concentrations (1 to 8 mM) of wild-type or C5A variants
were added to cells immediately after virus addition. After 48 h, HSV
infection was quantified by FACS by GFP content. Percentage of
infection in the absence of peptide was arbitrarily fixed at 100. Error
bars represent standard errors of duplicates. Results are representative
of two independent experiments.
doi:10.1371/journal.pone.0018917.g003
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for HIV-1 acquisition and transmission [1–3]. The prevalence of
HSV-2 infection among Africans with HIV-1 ranges from 50 to
90%. Asymptomatic shedding is common and is associated with
both a higher frequency and a larger amount of HIV-1 in genital
secretions. In the present study, we examined the possibility that
C5A neutralizes HSV. We found that C5A, at nM-mM range,
efficiently inhibits HSV-1 and HSV-2 infection in vitro. This is not
only true for immortalized cells such as Vero, corneal and
conjunctival epithelial cells, but also for primary cells such as
human DC and PGEC. Moreover, we showed that C5A blocks
HSV epidermis infection ex vivo. Thus, C5A neutralizes both HIV-
1 and HSV. Importantly, this dual inhibitory effect of C5A is
reminiscent of the result of two recent studies, which showed that
PPCM and cyclovir ProTides represent a new class of antivirals
that suppress both HIV-1 and HSV infection [26–27]. We are
aware that a high nM to low mM range inhibitory effect is not ideal
for a microbicidal candidate and that the activity of C5A will be
coital dependent. However, it is important to emphasize that we
are currently synthesizing a second generation of peptides using
C5A archetype and are testing them for antiviral activities in
genital fluids. Our goal is to identify a peptide, which is active at a
low nM range in genital fluids.
We previously examined the possibility that C5A prevented
HIV-1 transcytosis because it is toxic for PGEC [8]. PGEC were
Figure 4. C5A prevents HSV entry by rupturing the integrity of the viral membrane. A. Vero cells were seeded in a 24-well plate and
exposed the next day with HSV-1-GFP (MOI of 0.1) for 2 h at 4uC. Increasing concentrations (1 to 8 mM) of wild-type or the control non-amphipathic
C5A were then added to cells just prior to shifting the temperature to 37uC. After 2 h, HSV entry was quantified by measuring amounts of HSV capsid
internalized. Specifically, cells were washed, trypsinized and lysed. Amounts of HSV capsid in cell lysates were quantified by ELISA. Percentage of
entry in the absence of peptide was arbitrarily fixed at 100. Error bars represent standard errors of triplicates. Results are representative of two
independent experiments. B. HSV was initially concentrated by loading 20 mL of supernatant of HSV-1-GFP-infected Vero cells on a 20% sucrose
cushion. Pelleted viruses were resuspended in 1 mL PBS, incubated with wild-type C5A or the control non-amphipathic C5A variant (5 mM) for 30 min
at 37uC and immediately loaded over a 20–70% sucrose density gradient. Each gradient fraction (total of eight fractions) was analyzed for HSV capsid
and gD content by immunoblot. The sucrose gradient density of each fraction was determined by measuring the refractive index. Results are
representative of 2 independent experiments. C. Human PBMC (1 million) were exposed to increasing concentrations of chloroquine or C5A (0 to
100 mM). At day 1, 2 and 3, the percentage of trypan blue positive was carefully analyzed. Results are representative of 2 independent experiments.
doi:10.1371/journal.pone.0018917.g004
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exposed twice daily to high concentrations (200 mM) of C5A for a
week. To maintain a continuous exposure of cells to the peptide,
no washes were performed. Cell viability was evaluated by methyl
thiazol tetrazolium (MTT)-based colorimetric assessment. As a
control, cells were exposed to the detergent saponin. In contrast to
0.01% saponin, we found that C5A applied to cells at a
concentration of 10- to 100-fold greater than that which blocks
HIV-1 infection is not toxic to PGEC [8]. The fact that the
peptide disrupts the HIV-1 membrane without PGEC toxicity,
suggested that C5A prevents HIV-1 transmigration without
interfering with epithelial integrity [8]. This is in accordance with
our observation that C5A does not affect the cellular viability of
the epidermal explants (data not shown).
It remains to be understood why the integrity of the cellular
membrane is preserved, but not that of the viral membrane (i.e.,
HIV-1 and HSV). One simple possibility is that the viral
membrane is more fragile than the cell membrane. In this
scenario, the C5A-mediated destabilization of the membrane
would have a more dramatic effect on a viral than a cell
membrane. Another possibility is that the viral membrane is
enriched with a C5A ligand. In this scenario, a denser
concentration of C5A binding sites would pre-exist in the viral
membrane than in the cell membrane. Further work is required to
determine whether or not C5A can disrupt the integrity of all
enveloped viruses, and why C5A does not affect the cell
membrane even when used at high concentrations [8]. Neverthe-
less, the goal of this study is to determine whether C5A is a
multipurpose anti-HIV-1 microbicidal agent, which can dually
neutralize HIV-1 and HSV, and prevents HIV-1 transmission by
inhibiting multiple steps of HIV-1 transmigration through the
genital barrier.
We obtained evidence that treating HSV with C5A disturbs the
integrity of the viral membrane. This is consistent with our
previous observation that C5A disrupts the integrity of HIV-1 [8].
It is likely that the release of the viral glycoproteins – gp120 for
HIV-1 [8] and gD/B/H for HSV (this study) – results from the
disruption of the integrity of the viral membrane. It is important to
note that C5A corresponds to a small N-terminal region (amino
acid 3–20) of the HCV NS5A (477 amino acids) [7]. The sequence
of C5A encompasses the region responsible for the anchoring of
NS5A into the ER membrane [9]. Thus, one can envision that the
anchoring of multiple C5A molecules into the HIV-1 or HSV
membrane somehow distabilizes the integrity of the fragile viral
membrane, resulting in the release of components of the viral
membrane. We previously showed that pre-treating HIV-1 with
proteases does not abrogate the C5A-mediated HIV-1 rupture [8],
suggesting that the membrane-associated C5A ligand is not
proteinous. Further work is required to identify the C5A ligand
(i.e., a lipid) within the membrane HIV-1 and HSV. The C5A
ligand could represent a novel target for the development of anti-
HIV-1 microbicides.
Interestingly, C5A has a different impact on capsid cores of
HIV-1 and HSV. For HIV-1, C5A completely disrupted the
integrity of the capsid core reflected by the fact that all HIV-1
capsid proteins relocated to the top of the sucrose gradient upon
HIV-1 exposure to C5A [8]. We postulated that C5A disrupts the
integrity of HIV-1 capsid cores by destabilizing the physical
linkage between the mature conical capsid core and the viral
envelope [8]. In contrast, in this study we found that HSV capsid
proteins, rather than relocating to the top of the gradient after
HSV treatment with C5A, migrated deeper in the gradient,
suggesting that HSV capsid cores remain intact after C5A
treatment, but that the partial or complete removal of the lipidic
viral membrane by C5A, render them denser, explaining their
deepened migration in the gradient. These data suggest that the
HIV-1 capsid core is more fragile than the HSV capsid core after
viral membrane removal by C5A. Nevertheless, it is likely that the
C5A removal of the HIV-1 and HSV glycoproteins responsible for
viral entry suffices to neutralize the infectivity of these pathogens.
In this study, we used an in vitro transwell chamber assay that
mimics HIV-1 transcytosis through PGEC. We showed that HIV-
1 infectious particles transmigrate through PGEC in a gp160-
dependent manner. As we previously reported, the efficiency of
cell-free HIV-1 transcytosis is extremely poor [8], suggesting that
the genital epithelium serves as a major barrier against HIV-1
transmission. We confirmed that HSV infects PGEC and damages
the impermeability of the PGEC monolayer. The HSV infection
of PGEC significantly enhances HIV-1 transcytosis. It is important
to note that we found that the disruption of the PGEC barrier by
HSV is highly dependent on both the viral MOI and the length of
infection. Specifically, a high HSV MOI (0.1 to 1) totally disrupted
the PGEC barrier already 2 days post-infection. Moreover, a low
HSV MOI (0.005), as used in this study, greatly damaged the
PGEC barrier 4 to 5 days post-HSV infection. Surprisingly, PGEC
were constantly more resistant to the lytic effect of HSV than
immortalized genital epithelial cells. As mentioned above, the
enhanced endurance of PGEC to HSV infection remains to be
elucidated.
We found that C5A abolished the HSV-mediated enhancement
of HIV-1 transmigration, suggesting that C5A, by preventing
HSV infection of genital epithelial cells, preserves the integrity of
the PGEC monolayer. By demonstrating that C5A blocks HIV-1
transmission as well as HSV infection, especially with ACV-
resistant HSV strains, this study further suggests that C5A
represents an attractive microbicidal candidate. Supporting this
notion, we recently demonstrated that a topical application of C5A
offers complete protection against a vaginal challenge of HIV-1 in
a humanized BLT mouse transmission model [unpublished data].
It is important to note that a recent study indicates that C5A
possesses chemo-attractant properties [28]. If this is true, this
property may represent a concern for the use of C5A as
microbicide. For this reason, we are currently screening a second
generation of C5A derivates for their chemo-attractant properties.
Our goal is to identify a peptide with potent anti-HIV-1 activities,
but deprived of chemo-attractant properties.
In conclusion, C5A represents a multipurpose microbicide
candidate, which neutralizes both HIV-1 and HSV, and interferes
with mechanisms thought to be critical for HIV-1 sexual
transmission such as HIV-1 transcytosis and HSV-mediated
Table 2. Antiviral efficacy of C5A is preserved in genital fluids.
Seminal
Plasma
Cervical
Fluid
Vaginal
Mucus
L-aa C5A 4.6+/20.3 4.4+/20.2 4.8+/20.3
L-aa Non-Amphipathic C5A .500 .500 .500
D-aa C5A 1.4+/20.1 1.3+/20.2 1.5+/20.2
D-aa Non-Amphipathic C5A .500 .500 .500
TZM cells (100,000 cells/mL) were exposed to JR-CSF (1 ng of p24) for 4 h
together with increasing concentrations of C5A or control non-amphipathic
C5A peptide diluted in various conditions including DMEM (without serum),
seminal plasma (8 donors), cervical fluids (4 donors) or vaginal mucus (4
donors). Cells were then washed and infection was measured 48 h after
infection by b-galactosidase activity. Data are expressed as IC50 in mM. Results
are representative of 3 independent experiments.
doi:10.1371/journal.pone.0018917.t002
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disruption of the integrity of the genital epithelial barrier.
Development of a topical microbicide that targets both HIV-1
and HSV such as C5A may prove a powerful strategy for reducing
HIV-1 as epidemiological studies consistently demonstrate synergy
between these two pathogens.
Materials and Methods
Viruses
HSV-1 Syn17+, HSV-1 VP16-GFP [5], and HSV-2 333 were
grown and titrated on Vero cells. ACV- and GCV-resistant HSV
Figure 5. HSV enhances HIV-1 transmigration through the genital epithelial barrier. A. Model for the HIV-1 transwell assay. B. PGEC were
seeded onto polycarbonate membrane transwells and cultured until formation of tight junctions was achieved. HIV-1 (wild-type JR-CSF, NL4.3 or
gp160-deficient (DE) NL4.3) was then added to the apical surface of PGEC and amounts of transcytosed viruses were collected at various time points
(2, 4, 8 and 16 h) and quantified by p24 ELISA of the lower chamber corresponding to the basal surface. Data are expressed in percentage of the
original viral inoculum (top panel). Infectivity of transcytosed viruses: medium from the basal chamber was collected at different intervals of time,
filtered, standardized for p24 content (20 pg), and added to TZM indicator cells. Infection was measured 48 h post-infection by determining levels of
beta-galactosidase activity in cell lysates (bottom panel). Results are representative of the results of four independent experiments using PGEC
derived from each of the 4 donors. Error bars represent standard deviations. C. PGEC isolated from 2 donors were incubated with HSV-1 or HSV-2
(MOI of 0.005). Two days post-infection, infection of PGEC was quantified by FACS by anti-HSV gD IgG immunostaining. D. PGEC seeded onto the
transwells were exposed to HSV-1 or HSV-2 (MOI of 0.005) in the presence or absence of ACV (50 mmol/L). Two days post-infection, the integrity of
the PGEC barrier was analyzed by measuring the paracellular passage of the extracellular marker inulin (top panel) as well as the TER of each
monolayer (bottom panel) as we described previously [19].
doi:10.1371/journal.pone.0018917.g005
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isolates were obtained from G. Verjans. HIV-1 (wild-type JR-CSF,
NL4.3 or gp160-deficient NL4.3) viruses were produced by
transfection of 293T cells with JR-CSF, pNL4.3 or gp160-
deficient pNL4.3 DE proviral plasmids (obtained respectively from
I. Chen, M. Martin and N. Landau through the NIH AIDS
Research and Reference Reagent Program).
Figure 6. C5A prevents the HSV-mediated disruption of the genital epithelial cell barrier. A. PGEC monolayers were exposed to HSV-1,
HSV-2 (MOI of 0.005) or the nonionic detergent N9 (80 mg/mL) for 2 days. HIV-1 (wild-type JR-CSF) (1 ng of p24) was then added to the apical surface
of PGEC and amounts of crossed viruses were collected at various time points (2, 4, 8 and 16 h) and quantified by p24 ELISA of the lower chamber
corresponding to the basal surface. Data are expressed in percentage of the viral inoculum originally added to the upper chamber. B. Same as A,
except that just prior to HSV addition, ACV (50 mmol/L) was added to PGEC monolayers. C. Same as A, except that just prior to HSV addition, wild-type
C5A or control non-amphipathic C5A variant (5 mM) was added to PGEC monolayers.
doi:10.1371/journal.pone.0018917.g006
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Cells
TZM cells (obtained from J. C. Kappes, X. Wu, and Tranzyme
Inc. through the NIH AIDS Research and Reference Reagent
Program). TZM cells express CD4, CXCR4, and CCR5, which
render them susceptible to infection, and contain an integrated
Escherichia coli lacZ gene driven by the HIV-1 long terminal repeat
[20]. Upon infection, Tat production from the integrated provirus
leads to activation of the lacZ reporter, resulting in synthesis of
beta-galactosidase in these cells. Infected cells are identified by
enzymatic activity measurement 48 h post-infection, allowing
quantitation after a single round of infection as described
previously [20]. PGEC were provided by B. Kahn of the
Department of Obstetrics and Gynecology at the Scripps Clinic.
By rotation of cotton swabs against the vaginal walls, several
million cells were collected per individual. Cells were immediately
placed in sterile phosphate-buffered saline (PBS), held at 4uC, and
transported to the laboratory. After centrifugation (3006 g for
5 min), the cell pellet was digested in 1 mg/mL of collagenase-
dispase (Roche Molecular Biochemicals) containing 1 mg/mL of
DNase (Sigma) and 0.15 mg/ml of Na-p-tosyl-L-lysine chloro-
methyl ketone (Sigma) for 1 h at 37uC. The digest was spun down
(1,0006 g for 20 min) and resuspended in 250 mg/mL of PBS-
bovine serum albumin (PBS-BSA). After additional centrifugation,
the pellet was resuspended in 5 mg/ml of PBS-BSA and loaded
onto a 50% Percoll gradient. PGECs were then isolated from
contaminating cells by fluorescence-activated cell sorting (FACS)
as previously described [19] and propagated into collagen type I-
coated T-25 flasks in Dulbecco’s modified Eagle medium F12
medium containing 10% fetal calf serum and epithelial cell growth
supplement (100 mg/mL) (Sigma). We obtained ethics approval
from the Scripps IRB/Committee for the Protection of Human
Subjects approval for PGEC collections and at the Scripps hospital
where participants were recruited and human experimentation
was conducted. We obtained written informed consent from all
participants involved in the study. As a second source of PGEC,
cells were obtained from Whittaker (customized request). PGEC
were passaged fewer than three times prior to use in order to
maintain their original features. Vero and 293T cells were
generously obtained from C. Aiken, whereas human corneal and
conjunctival epithelial cell lines were provided by I. Gipson and G.
Verjans. Primary human DC were purified and characterized as
described previously [8].
In vitro and ex vivo infections
Cells (Vero, DC, corneal and conjunctival epithelial cells) were
seeded into a 24-well plate and infected with different concentra-
tions of HSV (HSV-1, -2 and HSV-1-GFP) together with C5A or
the DMSO control. C5A peptides were dissolved in DMSO and
subsequently diluted in RPMI or DMEM in the absence of serum.
Forty-eight hours post-infection, cells were harvested and stained
with antibodies against HSV glycoprotein gD (T111; Novus
biologicals, Littleton, CO, USA) for HSV-1 and -2 infection or
analyzed by flow cytometry for HSV-1-GFP infection. Cells were
washed and fixed with 4% PFA/PBS and analyzed by flow
cytometry. In some cases, cell morphology and GFP expression
were analyzed using a Leica DMIL fluorescence microscope (Leica
Microsystems Wetzlar, Germany) and pictures were taken using a
Leica DFC 320 camera (Leico Microsystems). Epidermal sheets
were prepared as we previously described [29]. The sheets were
infected with different concentrations of HSV-1-GFP by adding
the virus underneath the sheets into the medium. Different
concentrations of C5A or the appropriate volume of the DMSO
control solution was added in a total volume of 500 mL. After 2 h,
1.5 mL complete medium was added and the sheets were cultured
for 2 days. The sheets were analyzed by fluorescence microscopy
or by measuring GFP expression by flow cytometry. The
susceptibility of ACV- and GCV-resistant HSV isolates was
determined by real-time PCR (qPCR) assay as described
previously [16]. Briefly, Vero cells were inoculated with HSV-1
for 1 h at 37uC. Viral inoculum was removed and cells were
incubated, in triplicate, with different concentrations of ACV,
GCV or C5A. Twenty-four hours after inoculation, the superna-
tant was discarded and cells were treated with 300 mL of lysis
buffer (2.5 mmol/L MgCl2, 50 mmol/L KCl, 10 mmol/L Tris-
HCl, 0.45% Tween 20, 0.45% Nonidet-P40, and 200 mg/mL
proteinase K) and were incubated for 90 min at 56uC. A 10 mL
portion of the 10-fold diluted lysate was subjected to qPCR by use
of an Applied Biosystems 7000 Sequence Detection system as
described previously [16]. Viral load was determined on the basis
of a standard curve generated on a stock of HSV-1 strain McIntyre
counted by electron microscopy (Advanced Biotechnologies), and
the HSV-1 isolates were assayed at least 3 times. The IC50 was
defined as the concentration of antiviral drug that reduced viral
copies by 50% compared with what was observed for control
infected cells to which no antiviral drug was added.
HSV entry assay
Vero cells (100,000 cells) were seeded in a 24-well plate and
exposed to HSV-1-GFP (MOI of 0.1) at 4uC for 2 h. Increasing
concentrations (1 to 8 mM) of C5A peptides were then added to
cells just prior to shifting the temperature to 37uC. After 2 h, cells
were extensively washed, trypsinized and lysed. HSV entry was
quantified by measuring amounts of HSV capsid in cell lysates by
ELISA. Recombinant HSV capsid and anti-HSV capsid 3B6
monoclonal and NC1 polyclonal antibodies were used to establish
the HSV capsid sandwich ELISA.
Virus sedimentation assay
HSV was initially concentrated by loading 20 mL of superna-
tant of HSV-1-GFP-infected Vero cells on a 20% sucrose cushion.
Pelleted viruses were resuspended in 1 mL PBS, incubated with
wild-type C5A or control non-amphipathic C5A for 30 min at
37uC and immediately loaded over a 20–70% sucrose density
gradient. After ultracentrifugation at 20,000 rpm for 24 h in a
SW-41 T rotor, fractions (1 mL) were collected and tested for their
content of viral proteins. Each gradient fraction was analyzed for
HSV capsid and gD content by immunoblot. The sucrose gradient
density of each fraction was determined by measuring the
refractive index.
HIV-1 transmigration assay
PGEC were seeded onto the upper face of collagen I and
fibronectin-coated 12-mm-diameter, 3-mm-pore-size polycarbon-
ate membrane transwells at a density of 105 cells/well and were
cultured until formation of tight junctions was achieved. The
inserts were fed every two days. The monolayer on the filter
effectively divides the well into an apical compartment and a
basolateral compartment. To ensure the integrity of the PGEC
barrier, we monitored the elevated transepithelial electrical
resistance (TER) of each cell monolayer as we described previously
[19] using a Millicell-ERS Electrical Resistance System (Millipore,
Bedford, MA). The resistance of the polycarbonate membrane in
transwells was subtracted from all readings. To further monitor the
integrity of the PGEC barrier, we also measured the paracellular
passage of the extracellular marker inulin by determination of the
permeability coefficient as evaluated by a diffusion assay using
inulin as described previously [19]. Transwells with PGEC
monolayers were incubated under different experimental condi-
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tions in the presence of FITC-inulin (0.5 mg/mL) in the upper
well. At varying times during the experiment, 50 mL of apical and
basal media was withdrawn and the fluorescence was measured
using a fluorescence plate reader (BioTEK Instruments, Winooski,
VT). The flux into the apical well was calculated as the percentage
of total fluorescence administered into the basal well per cm2
surface area. The integrity of the PGEC monolayers was analyzed
before and after HSV exposure. After analyzing the integrity of the
monolayer on the transwell filters, PGEC were exposed to HIV-1
(added to the upper chamber) and release of HIV-1 into the basal
chamber was monitored by measuring amounts of particulate
capsid in the basal chamber by p24 ELISA. Infectivity of
transcytosed HIV-1 particles was scored on TZM reporter cells
as described above.
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